---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 21 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: published economic evaluations

No cost-effectiveness analysis or budget impact model of rinzimetostat was identified. Published U.S. models address comparators and the combination partner. A partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel from a U.S. health care perspective (60-month horizon, 3% annual discount for costs, January 2025 dollars) estimated 0.86 versus 0.76 QALYs, mean total costs of $165,958 versus $129,700, and an ICER of $358,990 per QALY gained; results were most sensitive to the overall survival hazard ratio and the per-cycle costs of both treatments. Authors employed by Sanofi, the manufacturer of cabazitaxel, state that the model used the price of 177Lu-DOTATATE as a proxy for a per-cycle cost of $32,062. A U.S. payer cost model of third-line cabazitaxel versus a second androgen receptor-targeted agent over 18 months estimated $323,095 (17%) in avoided total costs, driven by the management of symptomatic skeletal events and end-of-life care; the CARD trial used cabazitaxel 25 mg/m2, while 20 mg/m2 is used in U.S. practice. A U.S. payer model of genomic test-directed olaparib after a new hormonal agent (2019 dollars) estimated an ICER of $116,903 per QALY in one scenario and cost savings in the other. For darolutamide, a U.S. payer budget impact model in nmCRPC for a 1-million-member plan over 5 years estimated a budget increase of $158,640 ($0.0132 PMPM) in year 1 and savings of $149,240 ($0.0124 PMPM) by year 5, and a U.S. hospitalization budget impact analysis of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer reported a cumulative budget impact of -$9.71 per treated member per month over 5 years.

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/); [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/); [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/); [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/)

<a id="topic-4.1-2"></a>

#### Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model

> “In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.”
> “A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon.”
> “OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel.”
> “The analysis was conducted over a lifetime horizon of 60 mo with a 1-mo cycle length on the basis that over 99% of patients in our model transitioned to a terminal state within this period.”
> “An annual discount of 3% for costs was applied in the analysis in accordance with recommendations from the Second U.S. Panel on Cost-Effectiveness in Health and Medicine (17).”
> “All costs were adjusted to January 2025 U.S. dollars using the medical care component of the Consumer Price Index (23).”
> “In the base case analysis, 177Lu-PSMA-617 was associated with an average of 0.86 QALYs, compared with 0.76 QALYs for cabazitaxel. The mean total costs were $165,958 for 177Lu-PSMA-617 and $129,700 for cabazitaxel, resulting in an incremental cost of $36,258 and an incremental QALY gain of 0.10. This corresponded to an ICER of $358,990/QALY gained, exceeding the highest U.S. WTP threshold of $200,000/QALY.”
> “Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel.”
> “At WTP thresholds of $50,000/QALY, $100,000/QALY, and $200,000/QALY, the corresponding maximum cost per cycle that would make 177Lu-PSMA-617 cost-effective was $23,499, $24,885, and $27,656, respectively.”
> “Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.”

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/)

<a id="topic-4.1-3"></a>

#### Acquisition cost input of the lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model

> “The authors note that direct U.S. cost data for 177Lu-PSMA-617 were not available and therefore used the price of 177Lu-DOTATATE as a proxy, citing a pan-Canadian Oncology Drug Review (pCODR) report.”
> “The base-case per-cycle cost for 177Lu-PSMA-617 was $32,062, with a sensitivity range of $25,649–$38,474, reflecting a 20% variation around the base case (i.e., 80%–120%), consistent with the underlying Advanced Accelerator Applications model.”
> “Although the directional conclusion is unlikely to change, the magnitude of difference is likely greater than reported.”
> “Kyle Flannery, Paul Cavanaugh, and Kevin Steele are employees of Sanofi, the manufacturer of Jevtana (cabazitaxel) injection, and may hold shares or options in the company.”

Source: [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/)

<a id="topic-4.1-4"></a>

#### Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model

> “We aimed to estimate healthcare costs avoided with the use of cabazitaxel as a third-line (3 L) treatment versus a second ARTA from a US payer perspective.”
> “Given the short life expectancy for the target population (median OS of 11.0–13.6 months) [19], a time horizon of 18 months was used for the reference case analysis, and scenario analyses were conducted for time horizons of 6, 12, and 24 months.”
> “The economic analysis included the costs associated with the management of SSEs, AEs, and end-of-life care.”
> “Cabazitaxel, as compared with a second ARTA, was associated with 58 fewer hospitalization days and 2 fewer ICU days and was estimated to avoid $323,095 (€274,630, 17%) in total costs, driven by SSEs management and end-of-life care.”
> “The CARD trial evaluated the 25 mg/m2 dose of cabazitaxel, while 20 mg/m2 is routinely used in clinical practice in the US.”

Source: [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/)

<a id="topic-4.1-5"></a>

#### Genomic test-directed olaparib after a new hormonal agent: U.S. payer cost-effectiveness model

> “We aimed to evaluate the cost-effectiveness of genomic test-directed olaparib on MCRPC from the US payer perspective.”
> “A mathematical model combining a decision tree and partitioned survival model was established to measure the clinical and economic outcomes of olaparib and standard care for men with MCRPC who had disease progression while receiving a new hormonal agent.”
> “Direct medical costs were considered from a United States payer perspective, which was reported in 2019 United States dollars.”
> “Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.”

Source: [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

<a id="topic-4.1-6"></a>

#### Darolutamide in nonmetastatic castration-resistant prostate cancer: U.S. payer budget impact model

> “A budget impact model was developed to evaluate darolutamide for nmCRPC for a hypothetical 1-million-member plan over a 5-year period.”
> “Costs (drug acquisition, drug administration, and treatment-related adverse events [AEs]) were estimated for 2 scenarios: with and without darolutamide treatment for nmCRPC.”
> “Market share estimates were derived from interviews with physicians treating men with nmCRPC.”
> “For a plan with 1 million lives, there were approximately 90 incident cases of nmCRPC (46 high risk) each year, with 332 (109 high risk) treatment-eligible cases by year 5.”
> “Given the utilization of other agents, introducing darolutamide along with other targeted therapies was predicted to increase the total budget by $158,640 ($0.0132 per member per month [PMPM]) in year 1, which decreased over time to a cost savings of $149,240 ($0.0124 PMPM) by year 5.”

Source: [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/)

<a id="topic-4.1-7"></a>

#### Darolutamide with docetaxel in metastatic hormone-sensitive prostate cancer: U.S. hospitalization budget impact analysis

> “Based on these estimates, a budget impact analysis evaluated the hospitalization costs (including ICU admissions) and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.”
> “The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.”

Source: [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

##### Company estimate of the annual U.S. population with mCRPC previously treated with abiraterone

> “In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3.5 billion and total global addressable market of $7 billion.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-4.2.3-2"></a>

##### Abiraterone share of new androgen receptor pathway inhibitor prescriptions

> “Abiraterone remains the leading ARPI, maintaining >50% market share of new prescriptions over the last five years”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-4.2.3-3"></a>

##### Modeled annual U.S. incidence of mCRPC

> “The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.”
> “The nmCRPC clinical state contributed heavily to the mCRPC states (86%), while the incidence flow from the non-castrate state to mCRPC was <15%.”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-4.2.3-4"></a>

##### Androgen receptor pathway inhibitor use before mCRPC diagnosis and as first-line mCRPC treatment

> “Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.”
> “The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.”
> “Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-4.2.3-5"></a>

##### Treatment by line of therapy among Medicare beneficiaries with mCRPC

> “22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.”
> “The most common therapies were abiraterone (36%), enzalutamide (28%), and docetaxel (16%) for 1 L; enzalutamide (33%), abiraterone (28%), and docetaxel (15%) for 2 L; and docetaxel (24%), enzalutamide (19%), and abiraterone (17%) for 3 L.”
> “For 37% of all mCRPC patients, NHTs were the only life-prolonging therapy they received.”
> “For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

##### Medicare Part B payment limits for parenteral comparators and bone-targeted agents, October to December 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
| --- | --- | --- | --- | --- |
| J9043 cabazitaxel (Jevtana) | “Cabazitaxel injection” | “1 MG” | “231.688” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| Q2043 sipuleucel-T (Provenge) | “Sipuleucel-t auto cd54+” | “Per infusion (minimum 50 million cells)” | “55663.131” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J0897 denosumab (Xgeva) | “Denosumab injection” | “1 MG” | “29.856” | “17.885” |
| J3489 zoledronic acid | “Zoledronic acid 1mg” | “1 MG” | “17.673” | “20.000” |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1 microCurie” | “N/A” | “20.000” |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-2"></a>

##### Radium-223 dichloride: payment limit note in the Medicare Part B file

> “microCurie 100% AWP = $212.84”
> “microCurie 100% WAC = $177.37”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-3"></a>

##### Hospital outpatient payment rates for radiopharmaceuticals, October 2026

| HCPCS code and product | Short descriptor | APC | Payment rate | Minimum unadjusted copayment |
| --- | --- | --- | --- | --- |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1745” | “$180.422” | “$36.09” |
| A9607 lutetium Lu 177 vipivotide tetraxetan (Pluvicto) | “Lutetium lu 177 vipivotide” | “9054” | “$266.541” | “$53.31” |

Source: [CMS OPPS Addendum B (2026)](https://www.cms.gov/files/zip/October-2026-OPPS-Addendum-B.zip)

<a id="topic-4.2.4-4"></a>

##### Lutetium Lu 177 vipivotide tetraxetan: per-dose cost estimated from Medicare Administrative Contractor payment rates

> “We collected all identifiable MAC payment rates for 177Lu-PSMA-617 (HCPCS A9607) across publicly available MAC jurisdictions (JE, JF, JJ, JM, J6, JK, and J15), standardized rates to a per-millicurie basis, and used the median to reduce outlier influence. Assuming the use of a 200-mCi dose, this yielded an estimated per-dose cost of $55,522 (3).”
> “Although 177Lu-PSMA-617 was approved by the Food and Drug Administration in March 2022 (7), there remains no ASP-based benchmark for this agent within the CMS ASP framework; under the current reimbursement structure, such a benchmark would not be expected to emerge absent U.S. legislative or regulatory change (4–6).”

Source: [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/)

<a id="topic-4.2.4-5"></a>

##### Per-cycle costs in the U.S. lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model

| Input | Base case value (USD) | Range for sensitivity analysis (USD) |
| --- | --- | --- |
| Cost per cycle, lutetium Lu 177 vipivotide tetraxetan | “32,062” | “25,649–38,474” |
| Cost per cycle, cabazitaxel | “14,382” | “11,505–17,852” |
| Gallium Ga 68 PSMA PET/CT | “5,689” | “4,551–6,829” |
| End of life | “17,312” | “13,849–20,773” |

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/)

<a id="topic-4.2.4-6"></a>

##### Darolutamide wholesale acquisition cost

| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
| --- | --- | --- | --- | --- | --- |
| Nubeqa (darolutamide) 300 mg, 120 tablets | “Bayer” | “Nubeqa 300 mg tab 120 count” | “2026-01-01T00:00:00” | “847.20” | “15100.80” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27)

<a id="topic-4.2.4-7"></a>

##### Enzalutamide: Medicare negotiated price effective January 2027 and 2024 list price

| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2027 | List price for 30-day supply, CY 2024 | Discount of negotiated price from 2024 list price |
| --- | --- | --- | --- | --- |
| Xtandi (enzalutamide) | “Astellas Pharma US, Inc.” | “$7,004” | “$13,480” | “48%” |

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

> “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies.”
> “List prices are rounded to the nearest dollar and represent the Wholesale Acquisition Costs (WACs) for the selected drugs based on 30-day supply using CY 2024 prescription fills.”

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

<a id="topic-4.2.4-8"></a>

##### Company price assumption in the post-abiraterone addressable market estimate

> “Post-abiraterone mCRPC is a significant unmet need and commercial opportunity, representing a $3.5bn total addressable market annually in the US with lack of oral and well-tolerated therapies”
> “Note: Addressable market assumes current price of ARPIs for illustrative purposes.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary: inputs available and absence of a rinzimetostat price or model

No budget impact model of rinzimetostat was identified, and no rinzimetostat price has been published: ORIC has “no products approved for commercial sale”, and its $3.5 billion U.S. addressable market figure “assumes current price of ARPIs for illustrative purposes”. A plan building its own model would need the rinzimetostat price and the regimen studied in Himalayas-1, rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily. Published population inputs are ORIC's estimate of approximately 17,000 U.S. patients annually with mCRPC previously treated with abiraterone (company-reported), a modeled U.S. mCRPC incidence of 42,970 in 2020, and Medicare fee-for-service data in which abiraterone accounted for 36% of first-line mCRPC therapy and 42% of men received at least two lines. Published cost inputs are the darolutamide wholesale acquisition cost of $15,100.80 per bottle of 120 tablets of 300 mg (effective 1 January 2026), the 2027 Medicare negotiated price for enzalutamide of $7,004 per 30-day supply, and Medicare Part B payment limits for October to December 2026 for docetaxel ($0.471 per mg) and cabazitaxel ($231.688 per mg).

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
